The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 533-538

  Hiyoshi, Masaya ^a   Kitayama, Joji ^a   Kazama, Shinsuke ^a   Taketomi, Yoshitaka ^b   Murakami, Makoto ^b   Tsuno, Nelson H ^a   Hongo, Kumiko ^a   Kaneko, Manabu ^a   Sunami, Eiji ^a   Watanabe, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Colorectal cancer; Immuno histochemistry; Metastasis; Phospholipase A2

Indexed keywords

PHOSPHOLIPASE A2 GROUP X;

ADULT; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION;

EID: 84871583396     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1067     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest105: 1589-1594, 2000.
3. Rodrigues S, Bruyneel E, Rodrigue CM, Shahin E and GespachC: Cyclooxygenase 2 and carcinogenesis. Bull Cancer 91 (Suppl 2): S61-S76, 2004 (In French).
4. Murakami M, Taketomi Y, Sato H and Yamamoto K: Secreted phospholipase A2 revisited. J Biochem 150: 233-255, 2011.
5. Lambeau G and Gelb MH: Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77: 495-520, 2008.
6. Touqui L and Wu YZ: Interaction of secreted phospholipase A2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome. Acta Pharmacol Sin 24: 1292-1296, 2003.
7. Triggiani M, Granata F, Frattini A and Marone G: Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta 1761: 1289-1300, 2006.
8. Nevalainen TJ, Graham GG and Scott KF: Antibacterial actions of secreted phospholipases A2. Review. Biochim Biophys Acta 1781: 1-9, 2008.
9. Hanasaki K, Ono T, Saiga A, et al: Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells. J Biol Chem 274: 34203-34211, 1999.
10. Murakami M, Kambe T, Shimbara S, et al: Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J Biol Chem 274: 31435-31444, 1999.
11. Morioka Y, Ikeda M, Saiga A, et al: Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis. FEBS Lett 487: 262-266, 2000.
12. Surrel F, Jemel I, Boilard E, et al: Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators. Mol Pharmacol 76: 778-790, 2009.
13. Mounier CM, Wendum D, Greenspan E, Fléjou JF, RosenbergDW and Lambeau G: Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer 98: 587-595, 2008.
14. Tribler L, Jensen LT, Jørgensen K, et al: Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue. Anticancer Res 27: 3179-3185, 2007.
15. Degousee N, Ghomashchi F, Stefanski E, et al: Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem 277: 5061-5073, 2002.
16. Masuda S, Murakami M, Matsumoto S, et al: Localization of various secretory phospholipase A2 enzymes in male reproductive organs. Biochim Biophys Acta 1686: 61-76, 2004.
17. 2 research: from cells to animals to humans. Prog Lipid Res 50: 152-192, 2011.
18. Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T and Kudo I: Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2). J Biol Chem 280: 24987-24998, 2005.
19. Yamashita S, Yamashita J, Sakamoto K, et al: Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71: 3058-3064, 1993.
20. Yamashita S, Yamashita J and Ogawa M: Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69: 1166-1170, 1994.
21. Kiyohara H, Egami H, Kako H, et al: Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas. Int J Pancreatol 13: 49-57, 1993.
22. Jiang J, Neubauer BL, Graff JR, et al: Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 160: 667-671, 2002.
23. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ and Sved P: Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 240: 9-16, 2006.
24. Ying Z, Tojo H, Komatsubara T, et al: Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma. Biochim Biophys Acta 1226: 201-205, 1994.
25. Leung SY, Chen X, Chu KM, et al: Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 99: 16203-16208, 2002.
26. Xing XF, Li H, Zhong XY, et al: Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer. Histopathology 59: 198-206, 2011.
27. Buhmeida A, Bendardaf R, Hilska M, et al: PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol 20: 1230-1235, 2009.
28. Kashiwagi M, Friess H, Uhl W, et al: Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis. Gut 45: 605-612, 1999.
29. Ganesan K, Ivanova T, Wu Y, et al: Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 68: 4277-4286, 2008.
30. Graff JR, Konicek BW, Deddens JA, et al: Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 7: 3857-3861, 2001.
31. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
32. Reddy BS: Chemoprevention of colon cancer by dietary fatty acids. Cancer Metastasis Rev 13: 285-302, 1994.
33. Bendardaf R, Lamlum H, Ristämaki R, Korkeila E, Syrjänen K and Pyrhönen S: Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Tumour Biol 28: 212-220, 2007.
34. Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K and Pyrhönen S: Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. Acta Oncol 47: 1046-1053, 2008.
35. Cummings BS: Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 74: 949-959, 2007.